Cluzeau, T., Favreau, C., Bourgoin, M., Venton, G., Fanciullino, R., Boucher, M., Fileni, C., Benachour, S., Loschi, M., Dadone-Montaudie, B., Auberger, P., Jacquel, A., Robert, G. (2025). Venetoclax dosages, BH3 profiling, and bcl-2 expression predict response to azacitidine + venetoclax regimen in first line AML not eligible to intensive chemotherapy: First results of venetacible study. Blood. https://doi.org/10.1182/blood-2025-5250